GlassScriptPhysician profile
Naresh C Chandan
NPI 1811094550
$9,247.79
in general payments reported to CMS, 2019-2025
50 companies · $1,791 in 2025
The $1,791 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $926 · 2020: $527 · 2021: $1,605 · 2022: $1,065 · 2023: $1,657 · 2024: $1,677 · 2025: $1,791.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,944 · Consulting Fee: $175 · Education: $6.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,943.67 |
| Consulting Fee | $175.00 |
| Education | $6.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,132.05 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $841.07 | 2019-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Amgen INC. | $751.71 | 2019-2025 | Prolia, Repatha, Evenity |
| Lilly USA, LLC | $691.75 | 2019-2025 | Mounjaro, Zepbound, Amyvid |
| Astrazeneca Pharmaceuticals LP | $618.31 | 2019-2025 | Farxiga, Breztri, Lokelma |
| Glaxosmithkline, LLC. | $569.35 | 2020-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $423.33 | 2020-2025 | Xifaxan |
| Janssen Pharmaceuticals, INC | $413.40 | 2019-2023 | Xarelto |
| Abbvie INC. | $383.30 | 2019-2025 | |
| Pfizer INC. | $365.17 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $268.66 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $247.87 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $239.90 | 2019-2024 | Verquvo, Dificid, Belsomra |
| Astellas Pharma US INC | $235.04 | 2019-2025 | Veozah |
| Dexcom, INC. | $221.07 | 2023-2025 | Dexcom G6 Transmitter |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Naresh Chandan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.